After transplantation, microbiome diversity does not predict all clinical outcomes

A more diverse gut microbiome does not automatically mean a better clinical outcome. In patients receiving a hematopoietic cell transplant for a blood cancer, a study linked to a randomized trial did not find the expected association between microbial diversity at engraftment and non-relapse mortality at one year. Its primary endpoint was therefore not met.

Illustration of the gut microbiome studied in patients receiving a hematopoietic cell transplant.
NutritionEditorial illustration, not study data.

A microbiome study embedded in a transplant trial

Allogeneic hematopoietic cell transplantation can treat certain blood disorders, but carries a risk of numerous complications. One of these, graft-versus-host disease, occurs when the donor’s immune cells react against the recipient’s tissues.

The microbiome study accompanies a phase 3 trial comparing two strategies for preventing this complication, referred to in the abstract as PTCy and Tac/MTX. The researchers analyzed 2,575 stool samples collected over time from 304 participants, including 157 in the PTCy group and 147 in the Tac/MTX group.

Their main question concerned the association between microbiome diversity at neutrophil engraftment and non-relapse mortality at one year. The abstract reports no such association. This does not demonstrate that no relationship exists, but it does not confirm the main hypothesis under investigation.

Signals that depend on timing and treatment

Lower microbial diversity before transplantation was associated with shorter overall survival. However, this finding concerns a different measurement time point and a different clinical endpoint. It therefore does not directly contradict the lack of association observed for the primary endpoint.

In exploratory analyses, microbial diversity and absolute microbial abundance were lower in the PTCy group between days 14 and 28 after transplantation. The authors report that this difference persisted independently of exposure to antibiotics not used for prophylaxis.

The bacterium Clostridium scindens and secondary bile acid metabolism pathways were also less abundant after transplantation in the PTCy group. These observations describe biological differences without demonstrating that they lead to a complication or clinical improvement.

Why greater diversity alone cannot guide a decision

The abstract notes that the main trial had demonstrated the clinical superiority of the PTCy strategy for preventing graft-versus-host disease. Yet here, this strategy is accompanied by lower microbial diversity in some analyses. A microbiome indicator therefore cannot, on its own, be used to rank treatments.

The treatment comparison takes place within a randomized trial, but associations between the microbiome and survival do not prove that changing the microbiome would change survival. This study does not test a dietary intervention or supplement intended to improve transplant outcomes.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. Effect sizes and their uncertainty intervals are not provided in this excerpt. Several findings are exploratory. Safety data are referred to the main trial publication, which is not included in the dossier. Funding and conflicts of interest could not be verified. The findings concern patients receiving transplants for blood cancers, not the general population.

What we can take away

Microbiome diversity remains a measure that must be interpreted in light of the treatment, sampling time point, and clinical outcome being studied. These data do not justify changing prophylaxis or trying to increase microbial diversity through an unevaluated intervention.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.